Abstract: The present invention provides compositions and method for treating a subject having or suspected of having pulmonary dysfunction resulting from impaired alveolar macrophage (AM) development. The compositions comprise granulocyte-macrophage colony stimulating factor (GM-CSF) in formulations suitable for pulmonary airway administration.

Abstract: The present disclosure provides methods for treating a subject having a HER2 non-amplified (HER2-negative) cancer or low HER2 expressing (HER2-low) cancer, comprising detecting expression of a BCAR4 gene fusion in a biological sample from the subject. If expression of the BCAR4 gene fusion is detected, a HER2-targeted cancer treatment is administered to the subject; if expression of the BCAR4 gene fusion is not detected, a cancer treatment that is not HER2-targeted is administered to the subject. Methods of predicting response to a HER2-targeted cancer treatment and detecting BCAR4 or BCAR4 gene fusion activation are also provided.

Abstract: A screw locating system including an intramedullary nail, a locating hole at the distal end of the intramedullary nail, a locator pin including a hollow section, and a locating end configured to fit in the locating hole, a cap configured to fill in the locating hole when the locator pin is in the locating hole, a screw configured to securely hold the locator pin, and a jig configured to guide a user to locate at least one distal screw at the distal end of the intramedullary nail.

Abstract: The present disclosure is directed to compositions and methods of treating arthritogenic alphavirus infection. Compositions include a fusion protein comprising an Fc region, a first Mxra8 region, and a second Mxra8 region, wherein the fusion protein reduces inflammation and infection by an arthritogenic alphavirus. Methods include administering the fusion protein to a mammalian or non-mammalian subject to reduce or inhibit alphavirus infection.

Abstract: The present disclosure relates to methods of treating a tumor with a nucleotide vaccine (e.g., DNA vaccine encoding a tumor antigen) in combination with an IL-7. In some aspects, the IL-7 is administered after the administration of the nucleotide vaccine (e.g., after the peak expansion phase of the tumor-specific T cell immune response) or concurrently with the nucleotide vaccine.

Abstract: The present disclosure provides constructs that comprise (a) a TNF-related apoptosis-inducing ligand (TRAIL) trimer comprising three consecutive extracellular TRAIL domains fused together in a head-to-tail configuration; (b) an epitope binding agent, and (c) optionally one or more additional components, wherein the epitope binding agent competitively inhibits binding of P4-TR3 or HN1-TR3 to cell surface human mesothelin. Constructs of the present disclosure induce apoptosis in cells expressing human mesothelin and a death receptor (DR4 or DR5) on the cell's surface.

Abstract: The present invention is directed towards isolated antibodies that bind to IL12R?1. Specifically, anti-IL12R?1 antibodies, and methods of treatment using the antibodies are disclosed. The antibody is targeted against the beta 1 subunit of the receptors of IL-12 and IL-23 and is capable of blocking signaling by inflammatory cytokines IL-12 and IL-23, which could be useful in treating autoimmune inflammatory diseases, such as inflammatory bowel disease (IBD), RA, and psoriasis.

Abstract: The present disclosure provides for compositions and methods of use of CDK4/6 inhibitors to prevent therapy-related clonal hematopoiesis and associated myeloid neoplasms.

Abstract: Described herein are direct liquid fuel cells with an alkaline anodic fuel stream including a solution of liquid fuel such as alcohols, ethers, glycols or compounds of hydrazine, and an acidic cathode oxidant stream including a solution of a suitable oxidant such as hydrogen peroxide or a gas steam with 1% to 100% O2. These cells are used as primary stationary and/or mobile power sources and also function in a secondary role as range extenders when coupled with a primary power source.

Abstract: A method of using a catheter assembly for inserting in a fluid filled space in a body includes providing a main body having a first end portion and a second end portion. The first end portion is positioned within the fluid filled space. The second end portion is adjusted to extend outwardly from the fluid filled space when the first end portion is positioned within the fluid filled space. A catheter tip is connected to the second end portion of the main body. The catheter tip includes a housing having a cavity defined therein and a rotating element positioned within the fluid filled space. The rotating element is rotated within the cavity of the housing to impart movement of the first end portion of the main body within the fluid filled space.

Abstract: A micro-bioelectrochemical cell (?-BEC) device is disclosed that includes from 4 to 96 microfluidically connected of chambers, in which each chamber encloses a volume of about 1 ?L to 2 ?L. A working electrode, reference electrode, and counting electrode contacts each volume. The ?-BEC device includes a support layer coated with a working electrode layer, a microfluidics layer containing a plurality of wells, and an electrical layer containing the reference and counter electrodes. Methods of using the ?-BEC device to perform bioelectrochemical measurements of cells are also disclosed.

Abstract: Among the various aspects of the present disclosure is the provision of treatments, monitoring treatment or progression, or methods for detecting utDNA in a subject having or suspected of having a urinary tract-associated cancer.

Abstract: Among the various aspects of the present disclosure is the provision of a methods for increasing chemotherapy sensitivity or decreasing chemotherapy resistance using BET inhibitors.

Abstract: The present disclosure provides compositions comprising chemerin and the methods of use thereof. The compositions of the disclosure are useful in the treatment of cancer.

Abstract: Provided herein are methods for determining the severity of glaucoma using expression levels of GDF15. Determining the severity of glaucoma can aid in making treatment decisions.

Abstract: The present invention provides methods for treating pruritus having a neurogenic component in a subject in need thereof comprising administering a therapeutically effective amount of a JAK1 inhibitor based on a benzimidazole core, a purine core, or a pyrrolo pyridine core.

Abstract: A binary code similarity detection system that compares a target binary code to a source code by comparing the target binary code to a comparing binary generated by compiling the source code. Rather than using a comparing binary generated using a random or fixed compiling configuration, the system identifies the compiling configuration of the target binary code and compares the target binary code to a comparing binary generated using the same compiling configuration as the target binary code. The compiling configuration of the target binary code may be identified by a neural network (e.g., a graph attention network trained on attributed function call graphs of binary codes with known compiling configurations). The target binary code and the comparing binary may be compared using a graph neural network (e.g., a graph triplet loss network) that compares attributed control flow graphs of the of the target binary code and the comparing binary.

Abstract: The present disclosure relates generally compositions and methods of using the same for the treatment of proteinopathies (e.g. Alpha-1-antitrypsin deficiency, Non-alcoholic fatty liver disease, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Huntington's disease) with one or more proteotoxicity reducing agents.

Abstract: Various methods of diagnosing and monitoring a subject infected with a Plasmodium parasite are described. Also, compositions and methods for attracting mosquitos are also described.

Abstract: The present disclosure describes a fast-scanning optical-resolution photoacoustic (fsOR-PAE) endoscope for imaging vasculature within tissues in vivo that includes an ultrasonic transducer and a scanning mirror within a lumen of an elongate casing. The scanning mirror is configured to direct the laser pulses from the pulsed laser source to a focal spot outside the casing in a scanning pattern via an imaging window formed in the casing. The scanning mirror is further configured to direct a plurality of photoacoustic signals from the focal spot to the ultrasonic transducer via the imaging window.